<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
  <channel>
    <title>MabThera RSS News</title>
    <description>MabThera.com is a comprehensive resource for healthcare professionals outside the US who are interested in MabThera and the treatment of lymphomas.</description>
    <language>en</language>
    <link>http://www.mabthera.com</link>
    <image>
      <title>rssfeed</title>
      <url>http://www.mabthera.com/portal/servlet/service/servicePicture?serviceId=15300036&amp;pictureName=rssfeed</url>
      <link>http://www.mabthera.com</link>
    </image>
    <pubDate>Thu, 04 Jun 2009 00:00:00 CEST</pubDate>
    <managingEditor>welcome@mabthera.com</managingEditor>
    <webmaster>welcome@mabthera.com</webmaster>
    <item>
      <title>Standard induction and maintenance therapy</title>
      <link>http://www.mabthera.com/portal/mabthera/standard_induction_and_maintenance_therapy_2</link>
      <description />
      <pubDate>Thu, 04 Jun 2009 00:00:00 CEST</pubDate>
      <author>kernixc</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/standard_induction_and_maintenance_therapy_2</url>
      </source>
    </item>
    <item>
      <title>Prognostic factors</title>
      <link>http://www.mabthera.com/portal/mabthera/about_cll</link>
      <description />
      <pubDate>Tue, 14 Apr 2009 00:00:00 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/about_cll</url>
      </source>
    </item>
    <item>
      <title>Stages</title>
      <link>http://www.mabthera.com/portal/mabthera/stages_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 17:04:57 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/stages_cll</url>
      </source>
    </item>
    <item>
      <title>MabThera maintenance therapy</title>
      <link>http://www.mabthera.com/portal/mabthera/stages_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 17:00:48 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/stages_cll</url>
      </source>
    </item>
    <item>
      <title>Safety</title>
      <link>http://www.mabthera.com/portal/mabthera/diagnosis</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 16:37:35 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/diagnosis</url>
      </source>
    </item>
    <item>
      <title>Email alert</title>
      <link>http://www.mabthera.com/portal/mabthera/presenting_signs_and_symptoms_of_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 16:30:15 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/presenting_signs_and_symptoms_of_cll</url>
      </source>
    </item>
    <item>
      <title>Prognostic factors</title>
      <link>http://www.mabthera.com/portal/mabthera/presenting_signs_and_symptoms_of_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 16:23:25 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/presenting_signs_and_symptoms_of_cll</url>
      </source>
    </item>
    <item>
      <title>Possible factors that may contribute to CLL development</title>
      <link>http://www.mabthera.com/portal/mabthera/possible_factors_that_may_contribute_to_cll_development</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 15:49:17 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/possible_factors_that_may_contribute_to_cll_development</url>
      </source>
    </item>
    <item>
      <title>MabThera provides the longest time free from the burden of CLL</title>
      <link>http://www.mabthera.com/portal/mabthera/mabthera_is_well_tolerated_in_first-line_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 10:43:14 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/mabthera_is_well_tolerated_in_first-line_cll</url>
      </source>
    </item>
    <item>
      <title>MabThera is well tolerated in first-line CLL</title>
      <link>http://www.mabthera.com/portal/mabthera/mabthera_provides_the_longest_time_free_from_the_burden_of_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 10:37:29 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/mabthera_provides_the_longest_time_free_from_the_burden_of_cll</url>
      </source>
    </item>
    <item>
      <title>Brief prescribing information</title>
      <link>http://www.mabthera.com/portal/mabthera/mabthera_is_well_tolerated_in_first-line_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 10:26:27 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/mabthera_is_well_tolerated_in_first-line_cll</url>
      </source>
    </item>
    <item>
      <title>Brief prescribing information</title>
      <link>http://www.mabthera.com/portal/mabthera/treating_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 10:21:16 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/treating_cll</url>
      </source>
    </item>
    <item>
      <title>Presenting signs and symptoms of CLL</title>
      <link>http://www.mabthera.com/portal/mabthera/presenting_signs_and_symptoms_of_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 00:00:00 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/presenting_signs_and_symptoms_of_cll</url>
      </source>
    </item>
    <item>
      <title>Possible factors that may contribute to CLL development</title>
      <link>http://www.mabthera.com/portal/mabthera/about_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 00:00:00 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/about_cll</url>
      </source>
    </item>
    <item>
      <title>Diagnosis</title>
      <link>http://www.mabthera.com/portal/mabthera/about_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 00:00:00 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/about_cll</url>
      </source>
    </item>
    <item>
      <title>MabThera first-line in CLL</title>
      <link>http://www.mabthera.com/portal/mabthera/mabthera_is_well_tolerated_in_first-line_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 00:00:00 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/mabthera_is_well_tolerated_in_first-line_cll</url>
      </source>
    </item>
    <item>
      <title>Brief prescribing information</title>
      <link>http://www.mabthera.com/portal/mabthera/mabthera_provides_the_longest_time_free_from_the_burden_of_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 00:00:00 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/mabthera_provides_the_longest_time_free_from_the_burden_of_cll</url>
      </source>
    </item>
    <item>
      <title>MabThera first-line in CLL</title>
      <link>http://www.mabthera.com/portal/mabthera/mabthera_provides_the_longest_time_free_from_the_burden_of_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 00:00:00 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/mabthera_provides_the_longest_time_free_from_the_burden_of_cll</url>
      </source>
    </item>
    <item>
      <title>MabThera is well tolerated in first-line CLL</title>
      <link>http://www.mabthera.com/portal/mabthera/treating_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 00:00:00 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/treating_cll</url>
      </source>
    </item>
    <item>
      <title>MabThera provides the longest time free from the burden of CLL</title>
      <link>http://www.mabthera.com/portal/mabthera/treating_cll</link>
      <description />
      <pubDate>Thu, 09 Apr 2009 00:00:00 CEST</pubDate>
      <author>mabthera_team</author>
      <source>
        <title>MabThera RSS News</title>
        <url>http://www.mabthera.com/portal/mabthera/treating_cll</url>
      </source>
    </item>
  </channel>
</rss>


